Breaking News

Financial Report: AstraZeneca

January 31, 2013

Loss of exclusivity on multiple brands pummels results

4Q Revenues: $7.3 billion (-16%)

4Q Earnings: $1.5 billion (-8%)

FY Revenues: $28 billion (-17%)

FY Earnings: $6.3 billion (-18%)

Comments: U.S. revenues were down 23% in the quarter as a result of the loss of exclusivity for Seroquel IR. The negative impact of U.S. healthcare reform on revenue and costs in the quarter was approximately $250 million. Revenue in the Rest of World was down 9% and revenue in Western Europe was down 16%. Loss of exclusivity on Seroquel IR, Atacand, Nexium and Merrem, accounted for 85% of the revenue decline. There were a few bright spots in AZ’s newer products: Symbicort sales were up 8% (CER) to $891 million in the quarter, Faslodex sales were up 20% to $175 million, Onglyza sales were up 24% to $88 million, and Iressa sales were up 10% to $160 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks